Candidate vaccine efficacies (60%, 70% and 80%) were educated by preceding HCV vaccine modelling [32] and consultation with investigators involved in a current Phase I/II HCV preventive vaccine trial among PWID in the US (ClinicalTrials.gov identifier: “type”:”clinical-trial”,”attrs”:”text”:”NCT01436357″,”term_id”:”NCT01436357″NCT01436357). Sample size projections for the estimates of chronic HCV infection stratified by candidate Continue Reading